General Archive
![](https://www.lifearc.org/wp-content/uploads/2024/01/image-1.png)
-
News releases
Two major UK decisions announced on use of Alzheimer’s drug, lecanemab
Today, two major decisions have been made on lecanemab (Leqembi®) – the Alzheimer’s drug that we helped humanise, which slows the…
-
NEURii
Transforming care for people living with dementia through UK-based collaboration, NEURii. In partnership with Eisai, Gates Ventures, Health Data Research…
-
£30m partnership with UK DRI
£30m partnership with UK Dementia Research Institute The partnership will accelerate development of new treatments for people with dementia. Partnership…
-
News releases
LifeArc appoints new chair for neurodegeneration efforts
Today, we’re pleased to announce the appointment of Professor Roger Barker as Chair of our neurodegeneration efforts. Professor Barker is…
-
News releases
Seven neurodegeneration research projects receive £14.5m from LifeArc-UKDRI partnership
The first projects to be funded through LifeArc’s £30 million strategic partnership with the UK Dementia Research Institute (UKDRI) have…
-
News releases
LifeArc helps fund new research institute to accelerate the search for a cure for MND
A new research institute to accelerate the search for a cure for motor neuron disease (MND, also known as ALS),…
-
Articles & blogs
New Alzheimer’s treatment ‘lecanemab’ approved for use in the US
LifeArc played an instrumental role in the drug’s development through our antibody humanisation work.
-
News releases
New UK-based research project brings together world-leading institutions to transform care for people living with dementia
Brings together the world-leading expertise of Health Data Research UK, University of Edinburgh, LifeArc, Eisai and Gates Ventures
-
Articles & blogs
How LifeArc’s Neurodegeneration Translational Challenge is leading the charge against Motor Neurone Disease
June 21st is Global MND Awareness Day, a day to raise worldwide awareness of MND (Motor Neurone Disease) and to…
-
Articles & blogs
Alzheimer’s drug lecanemab approved by US regulator
LifeArc’s Chief Scientific Officer Dr Dave Powell comments on news that lecanemab has received regulatory and safety approval from the…
-
Articles & blogs
LifeArc plays key role in discovery of new Alzheimer’s treatment
LifeArc played an important part in the discovery of lecanemab, an experimental drug that has shown some benefits for people…
-
News releases
New £30 million translational partnership will accelerate development of new treatments for people with dementia
Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.